MEI Pharma CEO to Present at Stifel Healthcare Conference

          MEI Pharma CEO to Present at Stifel Healthcare Conference

Live Webcast from Boston on Wednesday, September 11

PR Newswire

SAN DIEGO, Sept. 5, 2013

SAN DIEGO, Sept. 5, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that Daniel P. Gold, Ph.D., President and Chief
Executive Officer, will present at the Stifel Healthcare Conference on
Wednesday, September 11, 2013 at 11:30 a.m. Eastern time from the Four Seasons
Hotel in Boston. A live webcast of the presentation can be accessed at
www.meipharma.com/investor. A replay will be available approximately one hour
after the presentation.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
being developed for advanced hematologic diseases, such as myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II
clinical trial of Pracinostat in combination with Vidaza (azacitidine) in
patients with MDS presented at the American Society of Hematology Annual
Meeting in December 2012 showed an overall response rate of 89% (eight out of
nine). In June 2013, the Company initiated a randomized, placebo-controlled
Phase II trial of Pracinostat in combination with Vidaza in patients with
previously untreated MDS. In addition, MEI Pharma is developing two drug
candidates derived from its isoflavone-based technology platform, ME-143 and
ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.